Recent Finacing
Recent Raise
SemaThera is a Montreal biotech developing anti-SEMA3A therapies; its lead candidate ST-102, a bispecific biological trap inhibiting SEMA3A and VEGF, being prepared for clinical trials in diabetic macular edema.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Semathera.
